SELLAS Life Sciences Group, Inc.
SLS
$1.82
-$0.09-4.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.74% | -17.13% | -2.49% | -9.50% | -0.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.74% | -19.88% | -13.88% | -16.27% | -5.74% |
| Operating Income | 18.74% | 19.88% | 13.88% | 16.27% | 5.74% |
| Income Before Tax | 23.75% | 24.24% | 17.30% | 15.77% | 4.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.75% | 24.24% | 17.30% | 15.77% | 4.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.75% | 24.24% | 17.30% | 15.77% | 4.55% |
| EBIT | 18.74% | 19.88% | 13.88% | 16.27% | 5.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 64.84% | 64.97% | 60.82% | 54.07% | 40.26% |
| Normalized Basic EPS | 63.24% | 63.64% | 59.75% | 54.31% | 40.59% |
| EPS Diluted | 64.53% | 64.93% | 60.79% | 54.05% | 40.23% |
| Normalized Diluted EPS | 63.24% | 63.64% | 59.75% | 54.31% | 40.59% |
| Average Basic Shares Outstanding | 103.31% | 117.37% | 120.33% | 99.44% | 73.31% |
| Average Diluted Shares Outstanding | 103.31% | 117.37% | 120.33% | 99.44% | 73.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |